JP2017517266A5 - - Google Patents

Download PDF

Info

Publication number
JP2017517266A5
JP2017517266A5 JP2016572447A JP2016572447A JP2017517266A5 JP 2017517266 A5 JP2017517266 A5 JP 2017517266A5 JP 2016572447 A JP2016572447 A JP 2016572447A JP 2016572447 A JP2016572447 A JP 2016572447A JP 2017517266 A5 JP2017517266 A5 JP 2017517266A5
Authority
JP
Japan
Prior art keywords
triphosphate
rna molecule
sequence
bioreactor
ntp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016572447A
Other languages
English (en)
Other versions
JP2017517266A (ja
JP6748579B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/001164 external-priority patent/WO2015188933A1/en
Publication of JP2017517266A publication Critical patent/JP2017517266A/ja
Publication of JP2017517266A5 publication Critical patent/JP2017517266A5/ja
Application granted granted Critical
Publication of JP6748579B2 publication Critical patent/JP6748579B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (17)

  1. 所与の配列のRNA分子を合成する方法であって、
    a)前記RNA分子における4種のヌクレオチドG、A、C、及びUの各割合(1)を求める工程と、
    b)配列最適化反応ミックス中でインビトロ転写によって前記RNA分子を合成する工程であって、前記配列最適化反応ミックスが、4種のリボヌクレオシド三リン酸(NTP
    )GTP、ATP、CTP、及びUTPを含み、前記配列最適化反応ミックス中の前記4種のリボヌクレオシド三リン酸の各割合(2)が、前記RNA分子、バッファ、DNAテンプレート、及びRNAポリメラーゼ中の各ヌクレオチドの割合(1)に対応する工程と
    を含むことを特徴とする方法。
  2. 前記工程b)が、
    b1)前記4種のリボヌクレオシド三リン酸(NTP)GTP、ATP、CTP、及びUTPを含む配列最適化リボヌクレオシド三リン酸(NTP)ミックスを調製する工程であって、前記配列最適化リボヌクレオシド三リン酸(NTP)ミックス中の前記4種のリボヌクレオシド三リン酸の各割合(2)が、前記RNA分子中の各ヌクレオチドの割合(
    1)に対応する工程と、
    b2)工程(b1)の前記NTPミックス、バッファ、DNAテンプレート、及びRNAポリメラーゼを含む配列最適化反応ミックス中でインビトロ転写によって前記RNA分子を合成する工程と
    を含む請求項1に記載の方法。
  3. 前記インビトロ転写の開始前に、前記RNA分子の第1のヌクレオチドに対応する出発ヌクレオチドを前記配列最適化反応ミックスに添加する請求項1から2のいずれかに記載の方法。
  4. 前記出発ヌクレオチドが、ヌクレオシド一リン酸、ヌクレオシド二リン酸、ヌクレオシド三リン酸、又はジヌクレオシド三リン酸、若しくはキャップアナログである請求項3に記載の方法。
  5. 前記出発ヌクレオチドが、前記RNA分子の第1の位置にみられる前記RNA分子におけるヌクレオチドの割合に比べて過剰に添加される請求項3から4のいずれかに記載の方法。
  6. 前記RNA分子の前記第1のヌクレオチドに対応しないヌクレオチドについて、前記割合(1)と前記割合(2)との差が最大10%である請求項1から5のいずれかに記載の方法。
  7. 少なくとも1つのリボヌクレオシド三リン酸の一部又は全てが、修飾ヌクレオシド三リン酸によって置換されており、前記修飾ヌクレオシド三リン酸が、好ましくは、シュードウリジン−5’−トリホスフェート、1−メチルシュードウリジン−5’−トリホスフェート、2−チオウリジン−5’−トリホスフェート、4−チオウリジン−5’−トリホスフェート、及び5−メチルシチジン−5’−トリホスフェートからなる群から選択される請求項1から6のいずれかに記載の方法。
  8. 前記インビトロ転写の過程で、請求項2のb1)に記載の前記配列最適化リボヌクレオシド三リン酸(NTP)ミックスを前記配列最適化反応ミックスに補充する請求項1から7のいずれかに記載の方法。
  9. 前記RNA分子が、非コードRNA分子及びコードRNA分子からなる群から選択され、好ましくはmRNAである請求項1から8のいずれかに記載の方法。
  10. 前記RNA分子が、100ヌクレオチドよりも長い、及び/又は所与の配列のRNA分子の合成が、大規模合成で実施される、及び/又は前記NTPの対イオンが、トリス(ヒドロキシメチル)−アミノメタン(Tris)である請求項1から9のいずれかに記載の方法。
  11. インビトロ転写による前記RNA分子の合成後に、未取り込みNTPを分離及び定量する請求項1から10のいずれかに記載の方法。
  12. インビトロ転写による前記RNA分子の合成が、バイオリアクタ(1)内で実施され、前記バイオリアクタ(1)が、好ましくは、固体担体に固定化されているDNAテンプレートを含む請求項1から11のいずれかに記載の方法。
  13. 前記バイオリアクタ(1)が、前記配列最適化反応ミックスからヌクレオチドを分離するための濾過膜(21)を含み、前記濾過膜(21)が、好ましくは、再生セルロース、変性セルロース、ポリスルホン(PSU)、ポリアクリロニトリル(PAN)、ポリメチルメタクリレート(PMMA)、ポリビニルアルコール(PVA)、及びポリアリールエーテルスルホン(PAES)の群から選択される請求項12に記載の方法。
  14. 前記濾過膜(21)が、約10kDa〜約50kDaの範囲の分子量カットオフを有する請求項13に記載の方法。
  15. 前記バイオリアクタ(1)が、反応中のヌクレオチド濃度をリアルタイムに測定するためのセンサユニット(41)を含み、前記センサユニット(41)が、好ましくは、光分析によって前記ヌクレオチド濃度を測定する請求項12から14のいずれかに記載の方法。
  16. 前記バイオリアクタが、請求項2のb1)に記載の前記配列最適化リボヌクレオシド三リン酸(NTP)ミックスの添加を制御する制御モジュール(4)を含む、及び/又は前記バイオリアクタ(1)が、請求項2のb1)に記載の前記配列最適化リボヌクレオシド三リン酸(NTP)ミックスを添加するアクチュエータ(43)を含む、及び/又は前記バイオリアクタ(1)が、前記RNA分子を捕捉し、転写反応ミックスの他の成分から前記RNA分子を分離するための樹脂を含む、及び/又は前記バイオリアクタ(1)が、半バッチモード又は連続モードで動作する請求項12から15のいずれかに記載の方法。
  17. 前記バイオリアクタ(1)が、少なくとも1つのイオン選択性電極を含み、前記少なくとも1つのイオン選択性電極が、好ましくは、前記バイオリアクタ(1)の少なくとも1つの区画に含まれる液体中の1種以上のイオンの濃度を測定するために用いられ、前記イオンが、好ましくは、H 、Na 、K 、Mg 2+ 、Ca 2+ 、Cl 、及びPO 3− からなる群から選択される請求項12から16のいずれかに記載の方法。
JP2016572447A 2014-06-10 2015-06-10 Rna生成を強化する方法及び手段 Active JP6748579B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2014/001577 2014-06-10
EP2014001577 2014-06-10
PCT/EP2015/001164 WO2015188933A1 (en) 2014-06-10 2015-06-10 Methods and means for enhancing rna production

Publications (3)

Publication Number Publication Date
JP2017517266A JP2017517266A (ja) 2017-06-29
JP2017517266A5 true JP2017517266A5 (ja) 2018-05-31
JP6748579B2 JP6748579B2 (ja) 2020-09-02

Family

ID=51033109

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016572447A Active JP6748579B2 (ja) 2014-06-10 2015-06-10 Rna生成を強化する方法及び手段

Country Status (15)

Country Link
US (2) US10837039B2 (ja)
EP (2) EP3155129B1 (ja)
JP (1) JP6748579B2 (ja)
KR (1) KR102459599B1 (ja)
CN (1) CN106661621B (ja)
AU (1) AU2015273933B2 (ja)
BR (1) BR112016026980B1 (ja)
CA (1) CA2945629C (ja)
ES (1) ES2727776T3 (ja)
MX (1) MX2016016170A (ja)
PL (1) PL3155129T3 (ja)
PT (1) PT3155129T (ja)
RU (1) RU2738753C2 (ja)
SG (1) SG11201608605QA (ja)
WO (1) WO2015188933A1 (ja)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
RS59037B1 (sr) 2011-06-08 2019-08-30 Translate Bio Inc Kompozicije lipidnih nanočestica i postupci za isporuku irnk
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
CA2903880A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Methods and compositions for delivering mrna coded antibodies
ES2967701T3 (es) 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
SG11201510746WA (en) 2013-08-21 2016-03-30 Curevac Ag Respiratory syncytial virus (rsv) vaccine
CA2925021A1 (en) 2013-11-01 2015-05-07 Curevac Ag Modified rna with decreased immunostimulatory properties
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
EP3540060A1 (en) 2013-12-30 2019-09-18 CureVac AG Methods for rna analysis
WO2015101416A1 (en) 2013-12-30 2015-07-09 Curevac Gmbh Methods for rna analysis
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
JP6748579B2 (ja) 2014-06-10 2020-09-02 キュアバック リアル エステート ゲゼルシャフト ミット ベシュレンクテル ハフツング Rna生成を強化する方法及び手段
EP4241784A3 (en) 2014-12-12 2023-11-15 CureVac SE Artificial nucleic acid molecules for improved protein expression
WO2016165825A1 (en) 2015-04-13 2016-10-20 Curevac Ag Method for producing rna compositions
EP3283125B1 (en) 2015-04-17 2021-12-29 CureVac Real Estate GmbH Lyophilization of rna
EP3289101B1 (en) 2015-04-30 2021-06-23 CureVac AG Immobilized poly(n)polymerase
EP3294885B1 (en) 2015-05-08 2020-07-01 CureVac Real Estate GmbH Method for producing rna
US11559570B2 (en) 2015-05-15 2023-01-24 CureVac SE Prime-boost regimens involving administration of at least one mRNA construct
US10517827B2 (en) 2015-05-20 2019-12-31 Curevac Ag Dry powder composition comprising long-chain RNA
CN107530448A (zh) 2015-05-20 2018-01-02 库瑞瓦格股份公司 包含长链rna的干粉组合物
EP3744843A1 (en) 2015-05-29 2020-12-02 CureVac Real Estate GmbH A method for producing and purifying rna, comprising at least one step of tangential flow filtration
WO2016193226A1 (en) 2015-05-29 2016-12-08 Curevac Ag Method for adding cap structures to rna using immobilized enzymes
US10501768B2 (en) 2015-07-13 2019-12-10 Curevac Ag Method of producing RNA from circular DNA and corresponding template DNA
US11225682B2 (en) 2015-10-12 2022-01-18 Curevac Ag Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
EP3373965A1 (en) 2015-11-09 2018-09-19 CureVac AG Rotavirus vaccines
AU2016375021B2 (en) 2015-12-22 2022-02-03 CureVac SE Method for producing RNA molecule compositions
US11248223B2 (en) 2015-12-23 2022-02-15 Curevac Ag Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
SG11201806340YA (en) 2016-02-17 2018-09-27 Curevac Ag Zika virus vaccine
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
KR102369898B1 (ko) 2016-04-08 2022-03-03 트랜슬레이트 바이오 인코포레이티드 다량체 코딩 핵산 및 그 용도
US11596699B2 (en) 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
EP3452493A1 (en) 2016-05-04 2019-03-13 CureVac AG Nucleic acid molecules and uses thereof
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
KR20190029576A (ko) 2016-06-09 2019-03-20 큐어백 아게 핵산 카고용 하이브리드 담체
EP3469074B1 (en) 2016-06-13 2020-12-09 Translate Bio, Inc. Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
CN109937253B (zh) * 2016-09-14 2023-06-30 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
WO2018096179A1 (en) 2016-11-28 2018-05-31 Curevac Ag Method for purifying rna
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
CN110582304A (zh) 2016-12-08 2019-12-17 库尔维科公司 用于治疗或预防肝脏疾病的rna
EP3558354A1 (en) 2016-12-23 2019-10-30 CureVac AG Lassa virus vaccine
EP3558355A2 (en) 2016-12-23 2019-10-30 CureVac AG Henipavirus vaccine
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
US11920148B2 (en) 2017-02-22 2024-03-05 Crispr Therapeutics Ag Compositions and methods for gene editing
MA47607A (fr) * 2017-02-27 2020-01-01 Translate Bio Inc Synthèse à grande échelle d'arn messager
CA3050614A1 (en) 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
EP3601576A1 (en) 2017-03-24 2020-02-05 CureVac AG Nucleic acids encoding crispr-associated proteins and uses thereof
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
WO2018195404A1 (en) * 2017-04-21 2018-10-25 The Board Of The Trustees Of The Leland Stanford Junior University Ultra-sensitive and universal species detection pipeline for next generation sequencing data
WO2018211038A1 (en) 2017-05-17 2018-11-22 Curevac Ag Method for determining at least one quality parameter of an rna sample
CN111328287A (zh) 2017-07-04 2020-06-23 库瑞瓦格股份公司 新型核酸分子
US11001868B2 (en) * 2017-08-11 2021-05-11 Global Life Sciences Solutions Operations UK Ltd Cell-free protein expression using double-stranded concatameric DNA
EP3673069A1 (en) 2017-08-22 2020-07-01 CureVac AG Bunyavirales vaccine
WO2019092153A1 (en) 2017-11-08 2019-05-16 Curevac Ag Rna sequence adaptation
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
AU2018392716A1 (en) 2017-12-20 2020-06-18 Translate Bio, Inc. Improved composition and methods for treatment of ornithine transcarbamylase deficiency
WO2019122371A1 (en) 2017-12-21 2019-06-27 Curevac Ag Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
EP3773702A2 (en) 2018-04-05 2021-02-17 CureVac AG Novel yellow fever nucleic acid molecules for vaccination
CN112292395A (zh) 2018-04-17 2021-01-29 库瑞瓦格股份公司 用于疫苗接种的新型rsv rna分子和组合物
EP3813874A1 (en) 2018-06-27 2021-05-05 CureVac AG Novel lassa virus rna molecules and compositions for vaccination
WO2020002598A1 (en) 2018-06-28 2020-01-02 Curevac Ag Bioreactor for rna in vitro transcription
AU2019410737A1 (en) 2018-12-21 2021-06-10 CureVac SE RNA for malaria vaccines
MX2021011031A (es) * 2019-03-11 2021-12-10 Modernatx Inc Proceso de transcripción in vitro en lotes alimentados.
US11578348B2 (en) * 2019-04-24 2023-02-14 The University Of Massachusetts Enzymatic methods to generate high yields of sequence specific rna with extreme precision
EP3986452A1 (en) 2019-06-18 2022-04-27 CureVac AG Rotavirus mrna vaccine
CA3144902A1 (en) * 2019-08-14 2022-01-19 Andreas Thess Rna combinations and compositions with decreased immunostimulatory properties
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
BR112022014627A2 (pt) 2020-02-04 2022-09-27 Curevac Ag Vacina contra coronavírus
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
WO2021168052A1 (en) * 2020-02-18 2021-08-26 Translate Bio, Inc. Improved processes for in vitro transcription of messenger rna
GB2597436A (en) * 2020-05-12 2022-02-02 Univ Cranfield A method and apparatus for RNA synthesis
JP2023528586A (ja) * 2020-05-12 2023-07-05 クランフィールド ユニヴァーシティー Rnaを用いた治療薬の合成方法及び合成モジュール式装置
EP3993828A1 (en) 2020-05-29 2022-05-11 CureVac AG Nucleic acid based combination vaccines
US20230272052A1 (en) 2020-07-31 2023-08-31 CureVac SE Nucleic acid encoded antibody mixtures
CA3170743A1 (en) 2020-08-31 2022-03-03 Susanne RAUCH Multivalent nucleic acid based coronavirus vaccines
EP4208286A1 (en) 2020-09-01 2023-07-12 CureVac RNA Printer GmbH Manufacturing device for a pharmaceutical product
CN116547077A (zh) 2020-11-27 2023-08-04 库瑞瓦格Rna打印机有限公司 用于通过毛细管聚合酶链式反应制备dna产物的设备
AU2021395736A1 (en) * 2020-12-09 2023-07-27 BioNTech SE Rna manufacturing
CA3205569A1 (en) 2020-12-22 2022-06-30 CureVac SE Rna vaccine against sars-cov-2 variants
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
CN114717230A (zh) * 2021-01-05 2022-07-08 麦塞拿治疗(香港)有限公司 成纤维细胞生长因子mRNA的无细胞和无载体体外RNA转录方法和核酸分子
CN114717229A (zh) * 2021-01-05 2022-07-08 麦塞拿治疗(香港)有限公司 治疗性mRNA的无细胞和无载体体外RNA转录方法和核酸分子
WO2022162027A2 (en) 2021-01-27 2022-08-04 Curevac Ag Method of reducing the immunostimulatory properties of in vitro transcribed rna
US20240181038A1 (en) 2021-03-26 2024-06-06 Glaxosmithkline Biologicals Sa Immunogenic compositions
AU2022305101A1 (en) * 2021-06-30 2024-02-01 Etherna Immunotherapies Nv Method for rna manufacturing
TWI814499B (zh) * 2021-07-22 2023-09-01 中央研究院 用以連續製備及分析rna的裝置以及利用該裝置來合成rna的方法
WO2023007019A1 (en) 2021-07-30 2023-02-02 CureVac SE Cap analogs having an acyclic linker to the guanine derivative nucleobase
AU2021461416A1 (en) * 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
US20230279376A1 (en) 2022-03-01 2023-09-07 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
TW202403046A (zh) 2022-03-21 2024-01-16 瑞士商Crispr治療公司 用於治療脂蛋白相關的疾病之方法及組成物
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2024068545A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
DE202023106198U1 (de) 2022-10-28 2024-03-21 CureVac SE Impfstoff auf Nukleinsäurebasis
WO2024089229A1 (en) 2022-10-28 2024-05-02 CureVac SE Improved formulations comprising lipid-based carriers encapsulating rna
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256555A (en) 1991-12-20 1993-10-26 Ambion, Inc. Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
US5434079A (en) 1993-02-12 1995-07-18 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and process for continuous in vitro synthesis of proteins
WO1995008626A1 (en) * 1993-09-20 1995-03-30 The Regents Of The University Of Colorado Strategy for the production of rna from immobilized templates
EP1800697B1 (de) 2001-06-05 2010-04-14 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
DE10240868A1 (de) * 2002-09-04 2004-03-18 Artus Gesellschaft für molekularbiologische Diagnostik und Entwicklung mbH Verbesserte Verfahren zur Synthese von Nukleinsäuren
EP1649056A1 (en) 2003-07-02 2006-04-26 Caliper Life Sciences, Inc. Methods for amplifying and detecting nucleic acids in microfluidic devices under continuous and non-continuous flow conditions.
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
US20050287539A1 (en) 2004-06-29 2005-12-29 Emmanuel Labourier Methods and compositions for preparing capped RNA
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
LT2578685T (lt) 2005-08-23 2019-06-10 The Trustees Of The University Of Pennsylvania Rnr, apimančios modifikuotus nukleozidus ir jų panaudojimo būdai
CA2659301A1 (en) 2006-07-28 2008-02-07 Applera Corporation Dinucleotide mrna cap analogs
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EA017740B1 (ru) 2007-06-19 2013-02-28 Борд Оф Сьюпервайзорз Оф Луизиана Стэйт Юниверсити Энд Эгрикалчурал Энд Мекэникал Колледж Синтез и применение антиинвертированных фосфоротиоатных аналогов кэп-структуры матричной phk
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
EP3346005A1 (en) 2008-01-31 2018-07-11 CureVac AG Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US20120208242A1 (en) 2009-10-21 2012-08-16 Riboxx Gmbh Method and RNA Reactor for Exponential Amplification of RNA
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
CA2801523C (en) 2010-07-30 2021-08-03 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
US9388373B2 (en) 2011-03-08 2016-07-12 University Of Maryland Baltimore County Microscale bioprocessing system and method for protein manufacturing
RS59037B1 (sr) 2011-06-08 2019-08-30 Translate Bio Inc Kompozicije lipidnih nanočestica i postupci za isporuku irnk
US9862926B2 (en) * 2011-06-27 2018-01-09 Cellscript, Llc. Inhibition of innate immune response
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
US8969545B2 (en) 2011-10-18 2015-03-03 Life Technologies Corporation Alkynyl-derivatized cap analogs, preparation and uses thereof
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
AU2013242404B2 (en) 2012-03-27 2018-08-30 CureVac SE Artificial nucleic acid molecules for improved protein or peptide expression
BR112014023898A2 (pt) 2012-03-27 2017-07-11 Curevac Gmbh moléculas de ácido nucleico artificiais compreendendo 5''utr top
KR102186497B1 (ko) 2012-03-27 2020-12-04 큐어백 아게 인공 핵산 분자
AU2013243951A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
EP3498267A1 (en) 2012-05-25 2019-06-19 CureVac AG Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
SG11201510746WA (en) 2013-08-21 2016-03-30 Curevac Ag Respiratory syncytial virus (rsv) vaccine
WO2015024664A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Composition and vaccine for treating prostate cancer
CA2915730A1 (en) 2013-08-21 2015-02-26 Karl-Josef Kallen A combination rsv/influenza a vaccine
CN105517569A (zh) 2013-08-21 2016-04-20 库瑞瓦格股份公司 狂犬病疫苗
SG11201510747RA (en) 2013-08-21 2016-03-30 Curevac Ag Method for increasing expression of rna-encoded proteins
HUE046469T2 (hu) 2013-08-21 2020-03-30 Curevac Ag Készítmény és vakcina tüdõrák kezelésére
CA2925021A1 (en) 2013-11-01 2015-05-07 Curevac Ag Modified rna with decreased immunostimulatory properties
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
BR112016014462A2 (pt) 2013-12-30 2017-10-24 Curevac Ag moléculas de ácido nucleico artificiais
WO2015101416A1 (en) 2013-12-30 2015-07-09 Curevac Gmbh Methods for rna analysis
ES2754239T3 (es) 2014-03-12 2020-04-16 Curevac Ag Combinación de vacunación y agonistas de OX40
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
JP6748579B2 (ja) 2014-06-10 2020-09-02 キュアバック リアル エステート ゲゼルシャフト ミット ベシュレンクテル ハフツング Rna生成を強化する方法及び手段
EP4241784A3 (en) 2014-12-12 2023-11-15 CureVac SE Artificial nucleic acid molecules for improved protein expression
WO2016097065A1 (en) 2014-12-16 2016-06-23 Curevac Ag Ebolavirus and marburgvirus vaccines
EP3240558A1 (en) 2014-12-30 2017-11-08 CureVac AG Artificial nucleic acid molecules
MX2017013321A (es) 2015-04-22 2018-07-06 Curevac Ag Composicion que contiene arn para tratamiento de enfermedades tumorales.
EP3294885B1 (en) 2015-05-08 2020-07-01 CureVac Real Estate GmbH Method for producing rna

Similar Documents

Publication Publication Date Title
JP2017517266A5 (ja)
RU2017100044A (ru) Способы и средства повышения продуктивности рнк
JP2016530294A5 (ja)
JP2019533476A5 (ja)
DK3039158T3 (en) MASSIVE PARALLEL SINGLE CELL CELL ANALYSIS
ES2827307T3 (es) Métodos y composiciones para la síntesis de ADNc y la elaboración del perfil del transcriptoma de células individuales utilizando una reacción de cambio de plantilla
RU2016107198A (ru) Аналоги нуклеотидов
EA202191796A2 (ru) Способ сайт-специфического ферментативного мечения нуклеиновых кислот in vitro введением не встречающихся в природе нуклеотидов
WO2020120442A3 (en) Direct oligonucleotide synthesis on cells and biomolecules
Kore et al. An improved protection-free one-pot chemical synthesis of 2′-deoxynucleoside-5′-triphosphates
WO2009102878A3 (en) Method for archiving and clonal expansion
ATE518948T1 (de) Verbesserte polymerasen
JP2016535983A5 (ja)
Toti et al. Nucleosides with transposed base or 4′-hydroxymethyl moieties and their corresponding oligonucleotides
WO2017058810A3 (en) Polymerase compositions and kits, and methods of using and making the same
Zhang et al. Synthesis of Threose Nucleic Acid (TNA) Triphosphates and Oligonucleotides by Polymerase‐Mediated Primer Extension
US20220195424A1 (en) Chemical Capping for Template Switching
BR112021021491A2 (pt) Método de amplificação de mrnas e para a preparação de bibliotecas de mrna de comprimento total
Kaur et al. Production of long linear DNA substrates with site-specific chemical lesions for single-molecule replisome studies
Li et al. Conformation-dependent DNA attraction
Kore et al. Gram‐scale chemical synthesis of 2′‐deoxynucleoside‐5′‐O‐triphosphates
JPWO2019199807A5 (ja)
Chemama et al. Flexible Nucleic Acids (FNAs) as Informational Molecules: Enzymatic Polymerization of fNTPs on DNA Templates and Nonenzymatic Oligomerization of RNA on FNA Templates
BR112017008508A2 (pt) método para purificar oses sem ajustar o ph
Wei et al. Towards Co-evolution of Membrane Transport and Metabolism